The widening net loss and accelerating cash burn without any clinical data catalyst are negative for the stock. The $0.54 EPS miss vs $0.36 consensus is a significant disappointment for a pre-revenue biotech. Monitor for the first clinical data readout from Ntrust-1 and Ntrust-2, expected at a medical conference in 2026, as the next potential catalyst.
Price Chart
Executive Summary
Nkarta reported Q2 2026 net loss of $0.54 per share, significantly missing the consensus estimate of -$0.36 per share. The net loss widened to $40.4 million from $23.0 million a year ago, driven by a 59% increase in operating expenses, including an $8.0 million impairment charge. Cash burn accelerated, with cash and investments declining to $243.2 million from $295.1 million at year-end 2025, though the company maintains a cash runway into 2029. No clinical data catalysts were announced, with initial data still expected at a medical conference in 2026.
Key Financial Metrics
Key Facts
- Net loss per share was -$0.54 vs consensus -$0.36, a 48.6% miss.
- Net loss widened to $40.4M in Q2 2026 from $23.0M in Q2 2025.
- Operating expenses surged 59% YoY to $43.1M, including an $8.0M impairment charge.
- Cash and investments fell to $243.2M from $295.1M at Dec 31, 2025, a $51.9M decline in six months.
- Cash runway guidance unchanged — expected to fund operations into 2029.
- No clinical data update; initial Ntrust-1 and Ntrust-2 data still planned for a medical conference in 2026.
Financial Impact
Net loss per share of -$0.54 missed consensus of -$0.36 by $0.18 per share. Net loss increased $17.4M YoY to $40.4M.
Risk Factors
- No approved products or revenue; continued operating losses.
- Cash burn accelerated to ~$26M/quarter in H1 2026 from ~$18M/quarter in H1 2025.
- Clinical-stage risk — NKX019 may fail to demonstrate efficacy or safety in ongoing trials.
- Potential need for future dilutive financing if cash runway shortens.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342402 |
| Document: nktx-20260810.htm | 0001193125-26-342402 |
| Document: 0001193125-26-342402-index-headers.html | 0001193125-26-342402 |
| Document: 0001193125-26-342402-index.html | 0001193125-26-342402 |
| Document: 0001193125-26-342402.txt | 0001193125-26-342402 |
| 8-K Data (Synthetic) | 0001193125-26-342402 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $2.33 $2.91 | ▼ −24.89% | ▼ −25.95% | $2.58 (−10.52%) |
May 12, 2026 20w ago | Press Release | $3.06 $2.76 | ▼ −9.80% | ▼ −9.19% | $2.58 (−15.85%) |
Apr 15, 2026 24w ago | Press Release | $2.80 $3.06 | ▲ +9.29% | ▲ +3.47% | $2.58 (−8.04%) |
Apr 6, 2026 25w ago | EFFECT | $2.36 $3.02 | ▼ −27.97% | ▼ −18.98% | $2.58 (−9.11%) |
Mar 26, 2026 27w ago | 8-K | $2.14 $2.92 | ▼ −36.45% | ▼ −25.78% | $2.58 (−20.33%) |
Mar 25, 2026 27w ago | S-3 | $2.14 $2.92 | ▼ −36.45% | ▼ −25.78% | $2.58 (−20.33%) |
Mar 25, 2026 27w ago | Press Release | $2.14 $2.92 | ▲ +36.45% | ▲ +25.78% | $2.58 (+20.33%) |
Feb 28, 2026 30w ago | Institutional Cluster | $2.70 $2.00 | ▼ −25.93% | ▼ −17.99% | $2.58 (−4.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access